Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression
Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in cons...
Gespeichert in:
Veröffentlicht in: | Cardiovascular research 1999-12, Vol.44 (3), p.527-535 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 535 |
---|---|
container_issue | 3 |
container_start_page | 527 |
container_title | Cardiovascular research |
container_volume | 44 |
creator | MURRAY, D. R PRABHU, S. D FREEMAN, G. L |
description | Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression.
Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg).
L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure.
Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload. |
doi_str_mv | 10.1016/S0008-6363(99)00226-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69441099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69441099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</originalsourceid><addsrcrecordid>eNpNkE2O1DAQRi0EYpqGI4C8QAgWgXIcO_ESjYBBGokFsLYcu8wYJXZjO4LsuRAX4Uykp1vAqvSVXv3oEfKYwUsGTL76CABDI7nkz5V6AdC2spF3yI71QjS87cRdsvuLXJAHpXzdohB9d59cMJAK2qHbkZ9XOCe3RjMHS9F7tLXQ5GkMNW-d9CM4pGWN9cYUpCHehDHUkCI1lZaKxq1bMRWpiY76NE3pe4hfaF3mlGlEm1MJhXpja8rN719NiG6x6Oi8JoeHjKVsyx6Se95MBR-d6558fvvm0-VVc_3h3fvL19eN5QOrjUADXA6Ky37k0AkF0knuJUcnrGvHEYCxAXrTOSWFEB3w3nuJauyG1rCR78mz095DTt8WLFXPoVicJhMxLUVL1XUMlNpAcQKP_5eMXh9ymE1eNQN91K9v9eujW62UvtW_pT15cj6wjDO6_6ZOvjfg6RkwxZrJZxNtKP-4FlrRSv4HWkeQNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69441099</pqid></control><display><type>article</type><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</creator><creatorcontrib>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</creatorcontrib><description>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression.
Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg).
L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure.
Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</description><identifier>ISSN: 0008-6363</identifier><identifier>EISSN: 1755-3245</identifier><identifier>DOI: 10.1016/S0008-6363(99)00226-6</identifier><identifier>PMID: 10690284</identifier><identifier>CODEN: CVREAU</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Analysis of Variance ; Angiotensin II - pharmacology ; Animals ; Biological and medical sciences ; Blood Pressure - drug effects ; Dogs ; Enzyme Inhibitors - pharmacology ; Female ; Fundamental and applied biological sciences. Psychology ; Heart ; Hemodynamics - drug effects ; Male ; Myocardial Contraction - drug effects ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitric Oxide Synthase - antagonists & inhibitors ; Stroke Volume - drug effects ; Tumor Necrosis Factor-alpha - pharmacology ; Ventricular Pressure - drug effects ; Vertebrates: cardiovascular system</subject><ispartof>Cardiovascular research, 1999-12, Vol.44 (3), p.527-535</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1202526$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10690284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MURRAY, D. R</creatorcontrib><creatorcontrib>PRABHU, S. D</creatorcontrib><creatorcontrib>FREEMAN, G. L</creatorcontrib><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><title>Cardiovascular research</title><addtitle>Cardiovasc Res</addtitle><description>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression.
Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg).
L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure.
Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</description><subject>Analysis of Variance</subject><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Dogs</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart</subject><subject>Hemodynamics - drug effects</subject><subject>Male</subject><subject>Myocardial Contraction - drug effects</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitric Oxide Synthase - antagonists & inhibitors</subject><subject>Stroke Volume - drug effects</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><subject>Ventricular Pressure - drug effects</subject><subject>Vertebrates: cardiovascular system</subject><issn>0008-6363</issn><issn>1755-3245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE2O1DAQRi0EYpqGI4C8QAgWgXIcO_ESjYBBGokFsLYcu8wYJXZjO4LsuRAX4Uykp1vAqvSVXv3oEfKYwUsGTL76CABDI7nkz5V6AdC2spF3yI71QjS87cRdsvuLXJAHpXzdohB9d59cMJAK2qHbkZ9XOCe3RjMHS9F7tLXQ5GkMNW-d9CM4pGWN9cYUpCHehDHUkCI1lZaKxq1bMRWpiY76NE3pe4hfaF3mlGlEm1MJhXpja8rN719NiG6x6Oi8JoeHjKVsyx6Se95MBR-d6558fvvm0-VVc_3h3fvL19eN5QOrjUADXA6Ky37k0AkF0knuJUcnrGvHEYCxAXrTOSWFEB3w3nuJauyG1rCR78mz095DTt8WLFXPoVicJhMxLUVL1XUMlNpAcQKP_5eMXh9ymE1eNQN91K9v9eujW62UvtW_pT15cj6wjDO6_6ZOvjfg6RkwxZrJZxNtKP-4FlrRSv4HWkeQNg</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>MURRAY, D. R</creator><creator>PRABHU, S. D</creator><creator>FREEMAN, G. L</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991201</creationdate><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><author>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Analysis of Variance</topic><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Dogs</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart</topic><topic>Hemodynamics - drug effects</topic><topic>Male</topic><topic>Myocardial Contraction - drug effects</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitric Oxide Synthase - antagonists & inhibitors</topic><topic>Stroke Volume - drug effects</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><topic>Ventricular Pressure - drug effects</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MURRAY, D. R</creatorcontrib><creatorcontrib>PRABHU, S. D</creatorcontrib><creatorcontrib>FREEMAN, G. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MURRAY, D. R</au><au>PRABHU, S. D</au><au>FREEMAN, G. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</atitle><jtitle>Cardiovascular research</jtitle><addtitle>Cardiovasc Res</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>44</volume><issue>3</issue><spage>527</spage><epage>535</epage><pages>527-535</pages><issn>0008-6363</issn><eissn>1755-3245</eissn><coden>CVREAU</coden><abstract>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression.
Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg).
L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure.
Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10690284</pmid><doi>10.1016/S0008-6363(99)00226-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-6363 |
ispartof | Cardiovascular research, 1999-12, Vol.44 (3), p.527-535 |
issn | 0008-6363 1755-3245 |
language | eng |
recordid | cdi_proquest_miscellaneous_69441099 |
source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Analysis of Variance Angiotensin II - pharmacology Animals Biological and medical sciences Blood Pressure - drug effects Dogs Enzyme Inhibitors - pharmacology Female Fundamental and applied biological sciences. Psychology Heart Hemodynamics - drug effects Male Myocardial Contraction - drug effects NG-Nitroarginine Methyl Ester - pharmacology Nitric Oxide Synthase - antagonists & inhibitors Stroke Volume - drug effects Tumor Necrosis Factor-alpha - pharmacology Ventricular Pressure - drug effects Vertebrates: cardiovascular system |
title | Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemodynamic%20effects%20of%20nitric%20oxide%20synthase%20inhibition%20at%20steady%20state%20and%20following%20tumor%20necrosis%20factor-%CE%B1-induced%20myodepression&rft.jtitle=Cardiovascular%20research&rft.au=MURRAY,%20D.%20R&rft.date=1999-12-01&rft.volume=44&rft.issue=3&rft.spage=527&rft.epage=535&rft.pages=527-535&rft.issn=0008-6363&rft.eissn=1755-3245&rft.coden=CVREAU&rft_id=info:doi/10.1016/S0008-6363(99)00226-6&rft_dat=%3Cproquest_cross%3E69441099%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69441099&rft_id=info:pmid/10690284&rfr_iscdi=true |